Pamorelin (Triptorelin)

Pamorelin is a GnRH agonist that modulates the hormonal axis involved in several endocrine‑related conditions.

• Prostate cancer: provides androgen suppression to slow tumor growth.
• Endometriosis: reduces estrogen production to alleviate pelvic pain and lesion progression.
• Assisted reproductive technology: controls ovarian stimulation timing during IVF cycles.
• Precocious puberty: delays early onset of secondary sexual characteristics.
• Uterine fibroids: decreases hormone‑driven fibroid growth.
• Hormone‑dependent breast cancer: contributes to estrogen suppression as part of combination therapy.

• Triptorelin is a synthetic decapeptide that binds with high affinity to GnRH receptors in the anterior pituitary gland. Continuous stimulation leads to receptor desensitization and down‑regulation, markedly reducing the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). The subsequent decline in downstream sex steroids—testosterone and estradiol—produces the therapeutic hormonal suppression required for its indicated uses.

Side effects vary with the degree of hormonal suppression and individual patient factors.

Common Side Effects

• Hot flashes
• Headache
• Injection site pain
• Mood changes
• Decreased libido
• Fatigue

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Cardiovascular events such as myocardial infarction
• Bone density loss leading to osteoporosis
• Liver function abnormalities
• Pituitary apoplexy (very rare)
• Severe depression or suicidal ideation

When prescribing Pamorelin, clinicians should consider several safety aspects.

• Cardiac monitoring: patients with existing heart disease may need regular ECGs.
• Bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation.
• Liver function: evaluate baseline hepatic enzymes and monitor periodically.
• Pregnancy and lactation: avoid use in women who are pregnant or breastfeeding.
• Drug interactions: review concomitant medications for potential hormonal effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Triptorelin may interact with other agents that influence hormonal pathways or cardiovascular status.

Major Interactions (Avoid)

• Combined androgen blockade therapies: may amplify hormonal suppression and cardiovascular strain.
• Long‑acting estrogen preparations: can increase risk of thromboembolic events.

Moderate Interactions (Monitor Closely)

• Anticoagulants: monitor coagulation parameters due to altered estrogen levels.
• CYP450‑modulating drugs: may affect metabolism of concomitant hormonal agents.
• Steroid hormones (e.g., corticosteroids): adjust dosing if significant hormonal fluctuations occur.
• Antidepressants: observe for mood changes that could be compounded by hormonal shifts.
• Herbal supplements such as St ").